Immunovant earnings for the second fiscal quarter ended September 30, 2026, will be released before the market opens on November 9. The company announced the schedule on October 21, with majority stockholder Roivant Sciences set to host a conference call that includes an Immunovant business update.
Key Takeaways
- Second-quarter financial results are scheduled for November 9, 2026, before market open.
- Roivant will host the live call and webcast at 8 a.m. Eastern Time that day.
- The announcement sets the reporting timetable but contains no quarterly financial results.
Table of Contents
Immunovant earnings timetable and call access
Immunovant’s second-quarter reporting announcement sets out two events for November 9: the financial results release and Roivant’s live conference call and webcast. The call will include a business update for Immunovant.
Participants who want to join by telephone must register online. Presentation and webcast details will be available under News & Events in the Investors section of Immunovant’s website, and an archived webcast will be available after the call.
| Item | Details |
|---|---|
| Reporting period | Second fiscal quarter ended September 30, 2026 |
| Results release | November 9, 2026, before market open |
| Conference call and webcast | November 9, 2026, at 8 a.m. Eastern Time, hosted by Roivant |
What the scheduled update covers
The release will cover Immunovant’s second fiscal quarter, rather than the calendar-year third-quarter label often used for a period ending September 30. The scheduling announcement does not disclose revenue, losses, cash balances or financial guidance.
Immunovant, which trades on Nasdaq under IMVT, is a clinical-stage immunology company developing targeted therapies for autoimmune diseases using anti-FcRn technology. It is a majority-owned subsidiary of Roivant Sciences, which trades on Nasdaq under ROIV.
Conclusion
The next confirmed milestone is the November 9 results release, alongside the scheduled 8 a.m. Eastern Time call carrying Immunovant’s business update.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
